Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia.

Boggs DL, Surti TS, Esterlis I, Pittman B, Cosgrove K, Sewell RA, Ranganathan M, D'Souza DC.

Schizophr Res. 2018 Apr;194:62-69. doi: 10.1016/j.schres.2017.03.047. Epub 2017 Apr 6.

2.

Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey.

Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA.

J Psychoactive Drugs. 2015 Nov-Dec;47(5):372-81. doi: 10.1080/02791072.2015.1107664. Epub 2015 Nov 23.

PMID:
26595349
3.

The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans.

Cortes-Briones JA, Cahill JD, Skosnik PD, Mathalon DH, Williams A, Sewell RA, Roach BJ, Ford JM, Ranganathan M, D'Souza DC.

Biol Psychiatry. 2015 Dec 1;78(11):805-13. doi: 10.1016/j.biopsych.2015.03.023. Epub 2015 Mar 30.

4.

GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC.

Radhakrishnan R, Skosnik PD, Cortes-Briones J, Sewell RA, Carbuto M, Schnakenberg A, Cahill J, Bois F, Gunduz-Bruce H, Pittman B, Ranganathan M, D'Souza DC.

Neuropsychopharmacology. 2015 Jul;40(8):2047-56. doi: 10.1038/npp.2015.58. Epub 2015 Mar 2. No abstract available.

5.

Δ9-THC Disrupts Gamma (γ)-Band Neural Oscillations in Humans.

Cortes-Briones J, Skosnik PD, Mathalon D, Cahill J, Pittman B, Williams A, Sewell RA, Ranganathan M, Roach B, Ford J, D'Souza DC.

Neuropsychopharmacology. 2015 Aug;40(9):2124-34. doi: 10.1038/npp.2015.53. Epub 2015 Apr 24.

6.

Testing differences in the activity of event-related potential sources: important implications for clinical researchers.

Cortes-Briones JA, Cahill JD, Ranganathan M, Sewell RA, D'Souza DC, Skosnik PD.

Clin Neurophysiol. 2015 Jan;126(1):215-8. doi: 10.1016/j.clinph.2014.04.008. Epub 2014 Apr 30. Review. No abstract available.

PMID:
24840905
7.

Effects of Δ9-tetrahydrocannabinol in individuals with a familial vulnerability to alcoholism.

Ranganathan M, Sewell RA, Carbuto M, Elander J, Schnakenberg A, Radhakrishnan R, Pittman B, D'Souza DC.

Psychopharmacology (Berl). 2014 Jun;231(12):2385-93. doi: 10.1007/s00213-013-3402-4. Epub 2014 Jan 15.

PMID:
24424782
8.

Pilot study of intravenous nicotine effects on cognitive performance in schizophrenia.

Boggs DL, Ranganathan M, Sewell RA, Madonick S, D'Souza DC.

Schizophr Res. 2013 Oct;150(1):323-4. doi: 10.1016/j.schres.2013.07.045. Epub 2013 Aug 13. No abstract available.

PMID:
23953216
9.

Acute effects of THC on time perception in frequent and infrequent cannabis users.

Sewell RA, Schnakenberg A, Elander J, Radhakrishnan R, Williams A, Skosnik PD, Pittman B, Ranganathan M, D'Souza DC.

Psychopharmacology (Berl). 2013 Mar;226(2):401-13. doi: 10.1007/s00213-012-2915-6. Epub 2012 Nov 24.

10.

Imaging changes in synaptic acetylcholine availability in living human subjects.

Esterlis I, Hannestad JO, Bois F, Sewell RA, Tyndale RF, Seibyl JP, Picciotto MR, Laruelle M, Carson RE, Cosgrove KP.

J Nucl Med. 2013 Jan;54(1):78-82. doi: 10.2967/jnumed.112.111922. Epub 2012 Nov 15.

11.

Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.

Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, D'Souza DC.

Biol Psychiatry. 2012 Nov 15;72(10):871-9. doi: 10.1016/j.biopsych.2012.06.012. Epub 2012 Jul 18.

12.

Pharmacogenetically driven treatments for alcoholism: are we there yet?

Arias AJ, Sewell RA.

CNS Drugs. 2012 Jun 1;26(6):461-76. doi: 10.2165/11633180-000000000-00000. Review.

13.

Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans.

D'Souza DC, Fridberg DJ, Skosnik PD, Williams A, Roach B, Singh N, Carbuto M, Elander J, Schnakenberg A, Pittman B, Sewell RA, Ranganathan M, Mathalon D.

Neuropsychopharmacology. 2012 Jun;37(7):1632-46. doi: 10.1038/npp.2012.8. Epub 2012 Feb 15.

14.

Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans.

Ranganathan M, Carbuto M, Braley G, Elander J, Perry E, Pittman B, Radhakrishnan R, Sewell RA, D'Souza DC.

Int J Neuropsychopharmacol. 2012 Oct;15(9):1251-64. doi: 10.1017/S1461145711001830. Epub 2012 Jan 16.

PMID:
22243563
15.

Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.

Johnson MW, Sewell RA, Griffiths RR.

Drug Alcohol Depend. 2012 Jun 1;123(1-3):132-40. doi: 10.1016/j.drugalcdep.2011.10.029. Epub 2011 Nov 29.

16.

The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.

Carbuto M, Sewell RA, Williams A, Forselius-Bielen K, Braley G, Elander J, Pittman B, Schnakenberg A, Bhakta S, Perry E, Ranganathan M, D'Souza DC; Yale THC Study Group.

Psychopharmacology (Berl). 2012 Feb;219(3):885-96. doi: 10.1007/s00213-011-2417-y. Epub 2011 Aug 16.

PMID:
21845389
17.

Does gamma-hydroxybutyrate (GHB) have a role in the treatment of alcoholism?

Sewell RA, Petrakis IL.

Alcohol Alcohol. 2011 Jan-Feb;46(1):1-2. doi: 10.1093/alcalc/agq086. Epub 2010 Dec 14. No abstract available.

PMID:
21156757
18.

Problem child is no headache.

Sewell RA, Gottschalk CH.

Headache. 2011 Feb;51(2):306; author reply 306-7. doi: 10.1111/j.1526-4610.2010.01808_1.x. Epub 2010 Nov 16. No abstract available.

PMID:
21083559
19.

Probing GABA receptor function in schizophrenia with iomazenil.

Ahn K, Gil R, Seibyl J, Sewell RA, D'Souza DC.

Neuropsychopharmacology. 2011 Feb;36(3):677-83. doi: 10.1038/npp.2010.198. Epub 2010 Nov 10.

20.

Clinical significance of neurological soft signs in schizophrenia: factor analysis of the Neurological Evaluation Scale.

Sewell RA, Perry EB Jr, Karper LP, Bell MD, Lysaker P, Goulet JL, Brenner L, Erdos J, d'Souza DC, Seibyl JP, Krystal JH.

Schizophr Res. 2010 Dec;124(1-3):1-12. doi: 10.1016/j.schres.2010.08.036. Epub 2010 Sep 19.

PMID:
20855185
21.

[Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia].

Sewell RA, Skosnik PD, Garcia-Sosa I, Ranganathan M, D'Souza DC.

Braz J Psychiatry. 2010 May;32 Suppl 1:S15-30. Review. Portuguese.

22.

New-onset dissociative disorder after electroconvulsive therapy.

Zaidner E, Sewell RA, Murray E, Schiller A, Price BH, Cunningham MG.

J ECT. 2010 Sep;26(3):238-41. doi: 10.1097/YCT.0b013e3181c3046c.

PMID:
19935087
23.

Cannabis and psychosis/schizophrenia: human studies.

D'Souza DC, Sewell RA, Ranganathan M.

Eur Arch Psychiatry Clin Neurosci. 2009 Oct;259(7):413-31. doi: 10.1007/s00406-009-0024-2. Epub 2009 Jul 16. Review.

24.

Cannabinoids and psychosis.

Sewell RA, Ranganathan M, D'Souza DC.

Int Rev Psychiatry. 2009 Apr;21(2):152-62. doi: 10.1080/09540260902782802. Review.

PMID:
19367509
25.

The effect of cannabis compared with alcohol on driving.

Sewell RA, Poling J, Sofuoglu M.

Am J Addict. 2009 May-Jun;18(3):185-93. doi: 10.1080/10550490902786934. Review.

26.

An atypical presentation of anton syndrome in a patient with preserved cognition despite multiple cerebral infarcts: a case report.

Davis GP, Sewell RA, Levy B, Price BH, Cunningham MG.

CNS Spectr. 2009 Jan;14(1):15-8. No abstract available.

PMID:
19169184
27.

Response of cluster headache to kudzu.

Sewell RA.

Headache. 2009 Jan;49(1):98-105. doi: 10.1111/j.1526-4610.2008.01268.x.

PMID:
19125878
28.

Cluster headache associated with moyamoya.

Sewell RA, Johnson DJ, Fellows DW.

J Headache Pain. 2009 Feb;10(1):65-7. doi: 10.1007/s10194-008-0081-3. Epub 2008 Nov 14. Erratum in: J Headache Pain. 2009 Feb;10(1):69. Johnson, Daren M [corrected to Johnson, Daren J].

29.

Norepinephrine and stimulant addiction.

Sofuoglu M, Sewell RA.

Addict Biol. 2009 Apr;14(2):119-29. doi: 10.1111/j.1369-1600.2008.00138.x. Epub 2008 Sep 22. Review.

30.

Doubts about the role of cannabis in causing lung cancer.

Sewell RA, Cohn AJ, Chawarski MC.

Eur Respir J. 2008 Sep;32(3):815-6. doi: 10.1183/09031936.00051108. No abstract available.

31.

Should electroconvulsive therapy be given to patients with intracranial vascular lesions?

Meyer F, Chang T, Sewell RA, Price BH, Cunningham M.

Rev Neurol Dis. 2007 Winter;4(1):43-50.

PMID:
17514158
32.
33.

Response of cluster headache to psilocybin and LSD.

Sewell RA, Halpern JH, Pope HG Jr.

Neurology. 2006 Jun 27;66(12):1920-2.

PMID:
16801660
34.

Hallucinogenic botanicals of America: a growing need for focused drug education and research.

Halpern JH, Sewell RA.

Life Sci. 2005 Dec 22;78(5):519-26. Epub 2005 Sep 26. Review.

PMID:
16188280
35.

More about parkinsonism after taking ecstasy.

Sewell RA, Cozzi NV.

N Engl J Med. 1999 Oct 28;341(18):1400; author reply 1401. No abstract available.

PMID:
10577096
36.

Extended biopsy followup after full course radiation for resectable prostatic carcinoma.

Sewell RA, Braren V, Wilson SK, Rhamy RK.

J Urol. 1975 Mar;113(3):371-3.

PMID:
804043
37.

Small bowel injury by angiographic contrast medium.

Sewell RA, Killen DA, Foster JH.

Surgery. 1968 Aug;64(2):459-65. No abstract available.

PMID:
5673061
38.

Experimental evaluation of a new angiographic contrast medium--isopaque 440.

Welborn MB Jr, Sewell RA, Killen DA, Foster JH.

Am J Roentgenol Radium Ther Nucl Med. 1967 Sep;101(1):224-8. No abstract available.

PMID:
6037337

Supplemental Content

Loading ...
Support Center